This disclosure relates to compositions for use in treatment of Alzheimer's Disease, and/or a ocular and retinal degenerative disease, such as age related macular degeneration. The described compositions include effective amounts of LLMe, the hydrobromide form thereof, or functional derivatives thereof. Methods of treatment of a retinal degenerative disease of Alzheimer's Disease using the described compositions are also provided.